摘要 |
<p>In the present invention, there is disclosed a topical formulation for the treatment of a dermatological condition, which comprises an immunosuppressive macrolide being selected from the group consisting of sirolimus, FK506, SDZ ASM 981 and pharmacologically active analogues, derivatives or pro-drugs thereof and a skin permeation modulator being selected from the group consisting of alkanoic acids and alkenic acids with the proviso that in case the immunosuppressive macrolide is FK506 then the permeation modulator differs from oleic acid wherein the skin permeation modulator and macrolide or the pharmacologically active analogue, derivative or pro-drug thereof are present in relative amounts such that when a therapeutic amount is applied to the skin a minimal systemic effect is produced.</p> |